MedTrace Logo

Study of Alofanib in Patients With Metastatic Gastric Cancer

NCT04071184 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-09-26

No results posted yet for this study

Summary

This is a non-randomized multicenter phase 1b clinical trial of the safety and pharmacokinetics, as well as the preliminary efficacy of monotherapy with alofanib, an allosteric fibroblast growth factor receptor 2 inhibitor, in patients with advanced gastric cancer who have exhausted the resource of standard therapy.

Conditions

Interventions

DRUG

Alofanib

Five dose cohorts and expanded cohort will be included

Sponsors & Collaborators

  • Russian Pharmaceutical Technologies

    lead INDUSTRY

Principal Investigators

  • Ilya Tsimafeyeu, MD · Scientific Adviser

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-26
Primary Completion
2020-10-01
Completion
2020-12-01

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04071184 on ClinicalTrials.gov